is janumet a glp 1 XR: Uses, Side Effects, Dosage & More Janumet XR | Australian Commission

Learn about the benefits and practical steps for transitioning patients from GLP-1 RAs to dual GLP-1/GIP receptor agonists, such as tirzepatide, to improve glycemic control in adults with type 2 diabetes.

Expert guidance on managing side effects, choosing nutrient-dense foods, and creating sustainable meal plans for optimal results with GLP-1 medications.

The global epidemic of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) and the high prevalence among individuals with type 2 diabetes has attracted the attention of clinicians specialising in liver disorders

- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Amylyx endocrine and neuroscience expertise and aligns with pipeline focus of delivering important potential treatment options to communities with high unmet needs - Phase 3 program for avexitide in PBH expected to begin in Q1 2025, with data readout anticipated in 2026

While other GLP-1R agonists have shown promising outcomes in mitigating cancer progression, the association between some GLP-1R agonists and an increased risk of cancer remains a topic requiring more profound investigation

Migraines can make sufferers lives a misery, with some left bedridden for days as they wait to recover